PIV5-SARS CoV-2 vaccine
- Generic Name
- PIV5-SARS CoV-2 vaccine
CyanVac's Intranasal COVID-19 Vaccine Candidate, CVXGA, Enters Phase 2b Trial
• CyanVac's CVXGA, an intranasal COVID-19 vaccine, has dosed its first participant in a Phase 2b clinical study.
• The trial, supported by Project NextGen, will compare CVXGA to an FDA-approved mRNA vaccine targeting the Omicron KP.2 variant.
• Approximately 10,000 adults will be enrolled, with initial safety data reviewed before broader enrollment proceeds.
• The study will assess CVXGA's efficacy in preventing symptomatic and asymptomatic SARS-CoV-2 infections over 12 months.
Blue Lake and CyanVac's Intranasal COVID-19 Vaccine Shows Promise in Phase 2a Trial
• Blue Lake and CyanVac reported positive Phase 2a clinical trial data for their intranasal COVID-19 vaccine candidate, CVXGA, demonstrating safety and efficacy.
• The trial showed a 78% reduction in the risk of symptomatic COVID-19 infection in participants who received CVXGA compared to the placebo group.
• CVXGA induced S-protein specific serum antibody responses in both younger (18-64 years) and older adults (65+ years), with good tolerability.
• The PIV5-vectored vaccine showed no significant difference in adverse reactions compared to placebo, suggesting a safe and well-tolerated profile.
Blue Lake and CyanVac Present Promising Intranasal Vaccine Data at ISV Annual Congress
• Blue Lake Biotechnology and CyanVac presented positive interim Phase 1/2a data for BLB201, an intranasal vaccine candidate against respiratory syncytial virus (RSV), in RSV-seropositive children.
• Phase 1 data for CVXGA, the companies’ intranasal vaccine candidate against COVID-19, demonstrated systemic and mucosal antibody responses and T cell-mediated responses.
• Preclinical data on a PIV5-based vaccine for Lyme disease, a collaboration with Immuno Technologies, showed protection against multi-strain _Borrelia burgdorferi_ in mice.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath